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This year’s Lasker DeBakeyClinical ResearchAward goes toNapoleone Ferrara for the discovery of
vascular endothelial growth factor (VEGF) as amajor mediator of angiogenesis and for the develop-
ment of an effective anti-VEGF therapy for wet macular degeneration, a leading cause of blindness
in the elderly.Many of us have been lured into a career
in science by the hope that we would
someday make a scientific discovery
benefiting patients suffering from a pre-
viously incurable disease. Only as we
progress in our careers do we realize
how difficult and rare such a discovery
is, not to mention how disconnected the
actual scientific discovery often is from
the development of a new therapeutic
based on that discovery. Thus it is excep-
tionally rare that a single individual not
only makes the seminal discovery but
also helps to champion the development
of an effective new class of therapeutics.
Napoleone Ferrara, recipient of this year’s
Lasker DeBakey Clinical Reseach Award,
provides a rare such example.
Ferrara’s landmark scientific discovery
involved the isolation and cDNA cloning
of vascular endothelial growth factor
(VEGF) as a mitogen for vascular endo-
thelial cells. In large part due to Ferrara’s
subsequent efforts, we now know that
VEGF is the most important driver in the
body of normal as well as pathological
blood vessel growth. We also now realize
that VEGF not only induces vessel sprout-
ing and growth but can also regulate
vessel function in other ways, so as to
regulate vascular tone and blood pres-
sure, as well as vessel wall integrity and
vascular permeability. The Lasker com-
mittee is recognizing Ferrara for the dis-
covery of VEGF and for his specific
contribution to the eye field, where he
played a key role in the development of
an anti-VEGF therapy for age-related
macular degeneration (AMD), a leading
cause of blindness in the elderly. Although
not directly acknowledged in the currentaward, Ferrara made arguably even
more exceptional contributions to the
parallel development of a similar therapy
for cancer.
Distinct Vascular Pathologies in Eye
Diseases and in Cancer
The vasculature plays a critical role in a
variety of eye diseases as well as in
cancer growth. In AMD, the most severe
vision loss occurs in patients who develop
the ‘‘wet form’’ of the disease character-
ized by choroidal neovascularization
(CNV). CNV refers to the growth of ab-
normal vessels originating from the cho-
roidal vascular network, directly under-
lying the retina. The abnormal vessels do
not usually invade the neural retina and
thus do not directly disrupt the retina
and its function. Instead, these abnormal
vessels become excessively leaky,
leading to retinal swelling and edema,
which in turn impairs vision. Optical
coherence tomography (OCT) can beauti-
fully image the living retina and reveal the
extent of swelling, including within the
macula and its foveal region, the tiny
central portion of the retina that is respon-
sible for the ‘‘central vision’’ critical to
important tasks such as reading and
driving. OCT images demonstrate that
patients with AMD can have marked
swelling in their central retina to over three
times normal thickness, resulting in
severe vision loss (Figure 1).
As Ferrara himself has thoroughly re-
viewed, theobservation that tumor growth
is associated with increased vascularity
was initially made over 100 years ago,
and this observation was then followed
by a series of classic papers over theCell 1following decades suggesting that tumors
might produce a diffusible factor that
stimulates angiogenesis, and that this
angiogenesis could be required for tumor
growth (Ferrara et al., 2004). The realiza-
tion that the apparently disparate vascular
pathologies in cancer and eye diseases
had a common trigger, and thus poten-
tially a related cure, awaited the discovery
and cloning of VEGF.
The Discovery and Cloning
of VEGF and VPF
In 1989, Ferrara and Henzel, working at
Genentech, reported the purification and
amino-terminal sequence of an endothe-
lial-specific mitogen; they termed this
protein VEGF. Shortly thereafter, Ferrara
and colleagues described the molecular
cloning of the cDNA encoding VEGF
(Leung et al., 1989). While Ferrara and
his colleagues focused on the endothelial
growth properties of this new protein, a
parallel effort was unknowingly trying to
purify and clone the same protein, but
with an eye toward a totally different
biological function. In 1983, the Dvorak
laboratory identified a tumor-derived
factor, which they termed ‘‘vascular per-
meability factor’’ (VPF), that rapidly and
potently induced microvascular perme-
ability and fluid leak but for which they
had no molecular sequence (Senger
et al., 1983); I remember first hearing the
VPF story directly from Dvorak in the
mid-1980s at Cold Spring Harbor when
he attended the cloning course that I
was teaching, along with Fred Alt and Al
Bothwell, in which Dvorak was trying to
gain the expertise to clone this intriguing
factor. Presumably because our training43, October 1, 2010 ª2010 Elsevier Inc. 13
Figure 1. Anti-VEGF Therapy forWet Age-RelatedMacular Degener-
ation
Swelling of the central retina in a patient with age-related macular degenera-
tion, as seen by optical coherence tomography, is reduced by treatment
with anti-VEGF therapy. Prior to treatment this individual could read 35 letters
on a specialized ‘‘ETDRS’’ eye chart. After treatment, this improved to 66.of Dvorak was not sufficient,
cloning of VPF was subse-
quently undertaken by the
Monsanto Company, which
published the amino-terminal
protein sequence as well as
the cDNA sequence in 1989
(Connolly et al., 1989; Keck,
1989).
Cloning of VEGF and VPF
revealed that they were the
same factor, and this conver-
gence showed that this new
factor had at least two fasci-
nating biologic activities—
not only could it induce
endothelial cell proliferation,
but it could cause vascular
leak and edema. Over the
next two decades, Ferrara
was the clear world leader in
further elucidating the biology
and pathological roles of this
new growth factor, helping
drive more widespread adop-
tion of VEGF as its name.
Ferrara early on realized the
value of using genetic inacti-
vation in mice, as well as en-
gineered biologics that could
work in multiple species,
as powerful tools. In 1996,
he demonstrated that early
mouse development de-pended on precise dosing of VEGF by
showing that inactivation of even a single
VEGF allele resulted in embryonic lethality
due to severe vascular abnormalities.
He cleverly developed and elegantly ex-
ploited biologics-based blockers (such
as antibodies and soluble receptors) to
show that VEGF is required for overall
postnatal growth, and to define its roles
in structures such as growing bones and
the cycling ovary (Gerber et al., 1999a,
1999b). He also worked with collabora-
tors to show that VEGF acted via an endo-
thelial-specific receptor tyrosine kinase,
further confirming that evolution had
selected VEGF to act specifically on the
vascular endothelium by limiting its
receptor distribution to these cells.
VEGF and Tumor Angiogenesis
As noted above, it had long been appreci-
ated that neo-angiogenesis accompanies
and might be required for tumor growth.
Building on this background, Folkman14 Cell 143, October 1, 2010 ª2010 Elsevierwas the first to propose that therapies
designed to prevent such angiogenesis
might provide a useful newway to combat
cancer (Folkman, 1971). Folkman, how-
ever, also presented a rather complicated
view of tumor angiogenesis in which there
were myriad positive and negative regula-
tors, almost all of which (such as fibroblast
growth factors, transforming growth
factors, collagen fragments known as
endostatin, and plasminogen fragments
known as angiostatin) served roles out-
side of the vasculature as well; Folkman
suggested that tumor angiogenesis de-
pended on a complex integration of these
various positive and negative regulators
but did not propose a specific angiogenic
pathway nor a key trigger. In contrast, Fer-
rara showed that angiogenesis depended
on a clear cascade of factors, with VEGF
as the key initiator of most angiogenic
processes; Ferrara’s demonstration of
the primacy of VEGF also pushed the field
to realize that additional growth factorsInc.had also evolved to specifi-
cally regulate the endothelium
by similarly utilizing endothe-
lial-specific receptors, such
as other members of the
VEGF family as well as the
more recently discovered
angiopoietin family (Yanco-
poulos et al., 2000).
Diligentlypursuinghis focus
on VEGF, Ferrara developed
amousemonoclonal antibody
to block VEGF, termed
A.4.6.1. It was initial experi-
ments using this antibody in
animal models that estab-
lished the primacy of VEGF in
tumor angiogenesis—Ferrara
showed that the antibody
could strongly inhibit tumor
growth by limiting tumor-
induced angiogenesis, not
only providing the first con-
vincing evidence that block-
ing tumor angiogenesis could
indeed prevent tumor growth
but simultaneously establish-
ing VEGF as the critical target
in the process (Kim et al.,
1993); importantly, the results
were reproduced in many
laboratories using an assort-
ment of VEGF-blocking re-
agents, including a clinicalcandidate termed the VEGF Trap that
was developed in our laboratory.
Despite the results with VEGF blockade
reported by Ferrara and others, the phar-
maceutical industry did not immediately
jump on VEGF as an exciting cancer
target. In part, this had to do with prevail-
ing views in the field that there were
myriad potential targets to attack, and
that no target was more important than
others. Ferrara pressed on and next
humanized A.4.6.1 so that it could be
used in human trials. This humanized
antibody, given the generic name bevaci-
zumab and the brand name Avastin, first
entered clinical trials in 1997. Bevacizu-
mab ultimately achieved FDA approval in
2004 as a first-line treatment for meta-
static colorectal cancer in combination
with chemotherapy, based on its statisti-
cally and clinically meaningful benefits
on progression-free survival and overall
survival (Ferrara et al., 2004), and has
since garnered additional approvals. The
bevacizumab story provides the definitive
demonstration that, in man, specific
antiangiogenesis blockade can provide
useful tumor control in multiple cancer
settings and is a testimonial to the efforts
and persistence of Ferrara, and it still
remains the standard for angiogenesis-
based therapeutics.
Kinase inhibitors that target the VEGF
receptor signaling pathway have since
been approved in cancer but do not
display as widespread activity while also
exhibitingbroader toxicities. Thereappear
to be several reasons for this. Biologics-
based therapies such as bevacizumab
are naturally selected to have high affinity
and great specificity for their target and
also have the benefit of long-circulating
half-lives following injection, allowing for
rather complete and long-term blockade
with little if any off-target activity, which
has proven more difficult to achieve with
small-molecule kinase inhibitors. Prob-
ably due to the confusion that marked
the field a few years ago, few biologics-
based VEGF-targeted therapies are in
late-stage clinical trials in cancer; it re-
mains to be seen whether either of the
two biologicals in phase III trials (that is,
the VEGF Trap or Lilly’s ramucirumab
that targets the VEGF receptor) will pro-
vide similar or even greater benefit than
bevacizumab.
Anti-VEGF Therapy for Eye
Diseases
Ferrara played a key role in the develop-
ment of anti-VEGF therapies for eye
diseases, an endeavor that depended on
the contributions and influence of several
key collaborators as well as independent
groups. First of all, it should be pointed
out that most believe it is the perme-
ability-inducing activity of VEGF, first
described by Dvorak, that leads to the
retinal swelling and edema that cause
vision loss inwet AMD; other eye diseases
(such as proliferative diabetic retinopathy)
do exhibit the profound pathologic neo-
vascularization that we now know is also
driven by VEGF. It was in the latter type
of settings that the first definitive link
between VEGF and human eye disease
was made, simultaneously in 1994 by
Adamis and colleagues as well as Aiello
and King working in collaboration with
Ferrara (Adamis et al., 1994; Aiello et al.,
1994); both groups showed markedincreases in VEGF levels in the eyes of
patients suffering from intraocular neo-
vascularization. Shortly thereafter, both
groups worked in collaboration with Fer-
rara to show the benefit of blocking
VEGF in animal models of ocular neovas-
cularization; Ferrara provided the critically
required anti-VEGF blocking reagents for
these seminal studies.
The introduction of anti-VEGF therapies
into theclinic for eyediseasescame froma
completely unexpected source, a small
company named NeXstar Pharmaceuti-
cals. This company was based on Larry
Gold’s ‘‘aptamer’’ technology, which was
being used to develop small synthetic
RNAs as a new class of drugs, and one
of their scientists, Nebojsa Janjic, was
developing an anti-VEGF aptamer with
cancer in mind; however, this aptamer
was ineffective when systemically admin-
istered in animal tumor models. Stimu-
lated by Adamis’ paper, Janjic reasoned
that his aptamer might work better if
directly injected into the eye. Toward this
end, Janjic met in 1996 with Adamis and
Guyer, who helped Janjic design a clinical
development plan for AMD. The aptamer,
termed Macugen, entered clinical trials in
1999. In the meantime, Adamis and Guyer
decided to try to start their own venture
and searched for the best available VEGF
inhibitor they could license for use in the
eye; it was at this point that I met the pair
as they became interested in our VEGF
Trap, and I became convinced by their
compelling rationale. Unfortunately, the
VEGFTrapwas then entangled in a collab-
oration with the Proctor & Gamble Health
Care group, which was not interested in
either developing it or out-licensing it for
the eye, and thus Adamis and Guyer had
to look elsewhere; several years later, we
were independently able to progress the
VEGF Trap into the clinic for eye diseases.
By 2000, Adamis and Guyer had started
a company called Eyetech and, not having
other options, licensed Macugen and
continued its clinical development. In
phase III, Macugen produced rather
modest results, somewhat slowing the
progressive visual decline of AMD but
was nevertheless approved by the FDA
in 2004; Pfizer entered into the mix and
paid a huge premium to obtain rights to
this innovative therapeutic.
Although temporally behind the Macu-
gen story, and certainly spurred by theCell 1competition, Ferrara and Genentech had
far superior VEGF blockers at their
disposal. Because of concerns that a
full-length antibody might not diffuse effi-
ciently into the retina when injected into
the vitreous, Ferrara and his colleagues
decided to engineer a humanized Fab
variant of A.4.6.1 for use in the eye that
was ultimately given the generic name
ranibizumab and the brand name Lucentis
(Ferrara et al., 2006). Ranibizumab had
other advantages over bevacizumab,
most notably a much higher affinity that
allowed it to be active at lower concentra-
tions, which Ferrara felt might be impor-
tant in terms of allowing for maintained
activity when the drug would drop to low
levels between monthly injections into
the eye. Genentech initially dosed
patients with ranibizumab in 2000 and
received FDA approval for the treatment
of wet AMD in 2006. The efficacy results
were quite stunning, especially when
compared to those obtained with the
poorer blocker, Macugen. Instead of
merely slowing vision loss, patients on
average gained vision and maintained
these gains if dosed on a monthly
schedule. Ranibizumab has since been
studied in other eye diseases and recently
gained approval for retinal vein occlusion.
Worldwide, Lucentis is now being used
to treat about a quarter million patients
a year. It perfectly fits the definition of
pharmaceutical blockbuster, in terms of
providing enormous clinical benefit to
many patients while simultaneously pro-
ducing enormous revenues. However,
there are emerging issues. In part frus-
trated by the cost of ranibizumab, clini-
cians explored off-label use of intravitreal
injection of bevacizumab for eye diseases
and claimed to see similar benefit (Rose-
nfeld, 2006). While there are certainly
concerns in terms of safety risks to
patients of such off-label use, the National
Eye Institute decided that the potential
pharmacoeconomic value of a lower-
priced alternative warranted running
clinical trials directly comparing ranibizu-
mab and bevacizumab in AMD; results
are expected in 2011. In addition, be-
cause patients and physicians are very
interested in decreasing the frequency of
eye injections, there have been many
attempts to study less frequent dosing
paradigms; despite these efforts, current
evidence supports the need for regular if43, October 1, 2010 ª2010 Elsevier Inc. 15
not monthly injection of ranibizumab to
optimize its benefit. Early studies with
other biologics blockers raise the possi-
bility that an even higher-affinity blocker,
perhaps at higher doses, could provide
further visual gains or allow for longer
interval dosing.
In many ways, Ferrara’s career repre-
sents the fulfillment of every drug discov-
erer’s dream, and the Lasker Award could
not be going to a more worthy recipient.
Ferrara not only made a seminal scientific
discovery, but then he and his colleagues
at Genentech built on this discovery to
spearhead the development of an entirely
new class of therapeutics with major
applications in two previously distinct
clinical arenas—vascular eye diseases
and cancer. Although Ferrara’s VEGF
antibody is now being used to treat
about 250,000 cancer patients a year,
the current award may have avoided
specifically acknowledging Ferrara’s
contribution to the cancer field because
of questions regarding the degree of clin-
ical benefit of bevacizumab in cancer.
Because bevacizumab represents an
entirely newway of attacking cancer, utili-
zation of this approach is still a work in
progress and may require new treatment
paradigms to optimize benefit. Traditional
treatment paradigms in which the anti-
cancer therapy is stopped after a short
treatment period when tumor killing is
thought to be completed, or after tumor
progression when the tumor is thought to
have become chemo-resistant, make little
sense for an antiangiogenesis approach:
the point is not to try to wipe out the tumor
initially but instead to provide ongoing
control by limiting host support; any
benefit would be expected to dissipate
as soon as such therapy is stopped. Ferra-
ra’s colleagues at Genentech have nicely
demonstrated this point in very recent
animal studies (Bagri et al., 2010), as well
as in recent clinical studies including one16 Cell 143, October 1, 2010 ª2010 Elsevierin ovarian cancer using an innovative
‘‘maintenance design’’ carried out by the
Gynecological Oncology Group (GOG-
0218). Data from this study can be used
to make several important points. First,
this study shows that, at least in this
setting, bevacizumab does not primarily
work by allowing more efficient delivery
of chemotherapy (as had been proposed
by others), given that the gained benefit is
at least as good during the monotherapy
maintenance stage as during the prior
combination stage. Moreover, the study
convincingly shows that continued main-
tenance with anti-VEGF therapy is neces-
sary to prevent loss of clinical benefit.
In addition to maintenance approaches or
treatment-through-progression strate-
gies, the benefit of anti-VEGF therapy
may also be improved by combining with
agents targeting other angiogenic path-
ways; notably, several companies are in
trials combining anti-VEGF agents with
otherantiangiogenicagents, suchas those
targeting Angiopoietin-2. Chemothera-
peutics may also be developed that work
better on tumors made hypoxic via antian-
giogenic therapy.Althoughantiangiogene-
sis approaches in cancer are likely to be
further optimized as the community learns
better how to take advantage of this
approach, there is little doubt that anti-
VEGF treatments pioneered by Ferrara
and his colleagues will long remain the
foundation of such efforts. Thus, it can be
hoped that this well-deserved Lasker
award for the discovery of VEGF and the
development of a treatment for AMD is
a harbinger of prestigious accolades to
come that would also include specific
recognition of Ferrara’s contributions to
tumor biology and cancer treatment.ACKNOWLEDGMENTS
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